Khalid Saad Alharbi, Mohammad Arshad Javed Shaikh, Syed Sarim Imam, Sultan Alshehri, Mohammed M. Ghoneim, Waleed Hassan Almalki, Sachin Kumar Singh, Deepak Kumar, Avvaru Praveen Kumar, Kamal Dua, Dinesh Kumar Chellappan, Keshav Raj Paudel and Gaurav Gupta* Pages 2061 - 2074 ( 14 )
More than 10 million people worldwide have Alzheimer's disease (AD), a degenerative neurological illness and the most prevalent form of dementia. AD's progression in memory loss, cognitive deterioration, and behavioral changes are all symptoms. Amyloid-beta 42 (Aβ42), the hyperphosphorylated forms of microtubule-associated tau protein, and other cellular and systemic alterations are all factors that contribute to cognitive decline in AD. Rather than delivering a possible cure, present therapy strategies focus on reducing disease symptoms. It has long been suggested that various naturally occurring small molecules (plant extract products and microbiological isolates, for example) could be beneficial in preventing or treating disease. Small compounds, such as flavonoids, have attracted much interest recently due to their potential to alleviate cellular stress. Flavonoids have been proven helpful in various ways, including antioxidants, anti-inflammatory agents, and anti-apoptotic agents, but their mechanism remains unknown. The flavonoid therapy of Alzheimer's disease focuses on this review, which includes a comprehensive literature analysis.
Flavonoids, Alzheimer's disease, antioxidant, amyloid-beta 42, cognitive deficits, anti-apoptotic.